Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Apr 01, 2016 3:02pm
167 Views
Post# 24721279

RE:RE:Richmond club presentation

RE:RE:Richmond club presentationGV, thanks for the concise summary.

The key to me is "As he says Resverlogix is no longer a one trick pony. It is a science platform." I have believed this for a long time. RVX and Zenith are not just rvx-208 and zen3694. These companies are really about a system of BET inhibitor development and as Don says, and I have doubted but am now beginning to believe, is  8 years or more advanced vs any competitor. In fact, from various posts I sense that competitors, if they exist, are on the wrong track. We must remember that from Dr Wong "RVX-208 modulates gene transcription and has effects on pathways known to play important roles in CVD risks including the complement, coagulation, inflammation, and metabolism as well as increasing levels of the apolipoprotein A-I (apoAI), the major protein in high density lipoprotein(HDL)."

So, among many benefits, apabetalone increases good, functional HDL cholesterol which may in turn explain the dramatic relative risk reduction in major cardiovascular events (MACE).

Very pleased that there are 2 deals in the works!

So GLTA
Toinv


Bullboard Posts